We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+17.86%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$345M
AUM Growth
+$3.48M
Cap. Flow
-$46.4M
Cap. Flow %
-13.44%
Top 10 Hldgs %
30.53%
Holding
110
New
11
Increased
34
Reduced
36
Closed
26

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$13.9M
2
CELG
Celgene Corp
CELG
+$10.8M
3
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$5.32M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$3.74M
5
MDVN
MEDIVATION, INC.
MDVN
+$3.4M

Top Sells

Rank Stock Value
1
UHS icon
Universal Health Services
UHS
+$10.3M
2
MDT icon
Medtronic
MDT
+$6.86M
3
ALKS icon
Alkermes
ALKS
+$6.27M
4
INCY icon
Incyte
INCY
+$4.12M
5
NPSP
NPS PHARMACEUTICALS INC
NPSP
+$4.03M

Sector Composition

Rank Sector Weight
1 Healthcare 80.57%
2 Consumer Staples 1.97%
3 Financials 1.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CELG
1
DELISTED
Celgene Corp
CELG
$20.4M 5.9%
182,000
+102,000
+128% +$10.8M
GILD icon
2
Gilead Sciences
GILD
$162B
$19.4M 5.63%
206,138
+134,138
+186% +$13.9M
CVS icon
3
CVS Health
CVS
$133B
$9.34M 2.71%
97,000
+25,000
+35% +$2.2M
REGN icon
4
Regeneron Pharmaceuticals
REGN
$78.5B
$9.23M 2.68%
22,500
+9,500
+73% +$3.74M
ABBV icon
5
AbbVie
ABBV
$443B
$9.16M 2.66%
140,000
+29,000
+26% +$1.83M
ALKS icon
6
Alkermes
ALKS
$8.22B
$8.37M 2.43%
143,000
-123,000
-46% -$6.27M
ALXN
7
DELISTED
Alexion Pharmaceuticals
ALXN
$8.14M 2.36%
44,000
-14,000
-24% -$2.59M
BIIB icon
8
Biogen
BIIB
$30B
$7.3M 2.12%
21,500
-7,500
-26% -$2.43M
MDVN
9
DELISTED
MEDIVATION, INC.
MDVN
$7.04M 2.04%
141,400
+65,400
+86% +$3.4M
AGN
10
DELISTED
Allergan plc
AGN
$6.95M 2.01%
27,000
+7,000
+35% +$1.75M
BMY icon
11
Bristol-Myers Squibb
BMY
$133B
$6.79M 1.97%
115,000
+16,000
+16% +$902K
UTI icon
12
Universal Technical Institute
UTI
$2.16B
$6.79M 1.97%
+61,000
New +$641K
UNH icon
13
UnitedHealth
UNH
$376B
$6.77M 1.96%
67,000
+32,000
+91% +$3.03M
RCPT
14
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$6.43M 1.87%
+52,526
New +$5.32M
AMGN icon
15
Amgen
AMGN
$208B
$6.24M 1.81%
39,168
+16,168
+70% +$2.52M
ESPR
16
DELISTED
Esperion Therapeutics
ESPR
$6.07M 1.76%
150,000
+67,079
+81% +$2.05M
RAD
17
DELISTED
Rite Aid Corporation
RAD
$5.9M 1.71%
39,250
-16,650
-30% -$1.85M
COV
18
DELISTED
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
$5.83M 1.69%
57,000
-19,000
-25% -$1.82M
CAH icon
19
Cardinal Health
CAH
$53.9B
$5.65M 1.64%
70,000
+11,000
+19% +$869K
BMRN icon
20
BioMarin Pharmaceuticals
BMRN
$11.6B
$5.51M 1.6%
61,000
-31,000
-34% -$2.58M
ACAD icon
21
Acadia Pharmaceuticals
ACAD
$4.43B
$5.24M 1.52%
165,000
-54,000
-25% -$1.53M
ELV icon
22
Elevance Health
ELV
$81.5B
$5.15M 1.49%
41,000
+6,000
+17% +$741K
CLVS
23
DELISTED
Clovis Oncology, Inc.
CLVS
$4.78M 1.39%
85,398
+28,398
+50% +$1.49M
LLY icon
24
Eli Lilly
LLY
$1.02T
$4.55M 1.32%
66,000
+36,000
+120% +$2.43M
MRK icon
25
Merck
MRK
$322B
$4.54M 1.32%
83,840
+15,720
+23% +$876K
1
2 3 4 5

Similar funds

BBI
Baxter Bros Inc Riverside, Connecticut $810M AUM 16.24% 1-Year Est. Return
SSG
Summit Securities Group New York $810M AUM 27.35% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
DWA
Dorsey Wright & Associates Pasadena, California $807M AUM 65.46% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return

Rhenman & Partners Asset Management's Q4 2014 Portfolio in Review

As of Q4 2014, Rhenman & Partners Asset Management held 110 positions worth $345M, up 1% from $342M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $46.4M in Q4 2014, closing 26 positions and reducing 36 holdings. Its most notable exit was Universal Health Services, an estimated $10.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, up from 79% a quarter earlier, followed by Consumer Staples and Financials.

Against the trend, Rhenman & Partners Asset Management opened a new position in RECEPTOS INC COM STK (DE) worth $6.43M.

  • Rhenman & Partners Asset Management's largest Q4 2014 buy was RECEPTOS INC COM STK (DE): 52,526 shares worth $6.43M.
  • Rhenman & Partners Asset Management added most to Gilead Sciences in Q4 2014, an estimated $13.9M increase.
  • Rhenman & Partners Asset Management's biggest Q4 2014 reduction was Medtronic, cutting an estimated $6.86M.
  • Rhenman & Partners Asset Management fully exited Universal Health Services in Q4 2014, selling an estimated $10.3M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 31% of its $345M portfolio in Q4 2014.
  • Rhenman & Partners Asset Management opened 11 new positions and closed 26 in Q4 2014.
  • Rhenman & Partners Asset Management's portfolio value rose 1% quarter-over-quarter to $345M.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2014, filed 9 Feb 2015.